Here are some useful Articles

Amgen NASDAQ: AMGN pharmaceutical powerhouse just released information stating positive performance results for denosumab Pivotal Postmenopausal Osteoporosis Trial.

Trial met primary endpoint of Reducing new vertebral fractures and secondary endpoints of decreasing time to first non-vertebral and hip fractures; adverse events similar to placebo. The immediate past president of the National Osteoporosis Foundation was excited." I am particularly excited about these findings because they indicate that denosumab may offer an important new option for patients."

Denosumab is the premier fully human monoclonal antibody in late stage clinical development that particularly targets RANK Ligand, an essential regulator of osteoclasts (these are the cells that break the bone down). Denosumab is being considered for its potential to inhibit all stages of osteoclast activity through a targeted mechanism. Denosumab is being researched in a range of bone loss illnesses including rheumatoid arthritis, postmenopausal osteoporosis, and cancer treatment-induced bone loss in breast cancer and prostate cancer patients| in prostate cancer and breast cancer patients as well as for its potential to defer bone metastases and inhibit and treat bone destruction across many stages of cancer.

Osteoporosis is often referred to as the "silent epidemic", osteoporosis is a world wide problem illness that is growing in dominance as the world population both ages and increases. WHO, The World Health Organization has recently claimed osteoporosis as a significant health issue along with other major non-communicable diseases. We are dependent on the pharmaceutical industry to help combat this terrible disease.

According to Amgen the financial burden of osteoporosis is referred to as the "silent epidemi' to that of other major chronic diseases; for example, in the U.S. the costs associated with osteoporosis-related fractures are equivalent to those of cardiovascular disease and asthma (i)(ii)(iii). It has been reported that osteoporosis results in more hospital bed-days than stroke, myocardial infarction or breast cancer (iv).

Clinical pharmacist have been developing prescriptions drugs to help patient that have serious side effects. These products are developed simultaneously the medications that assist in the treatment of the initial illness. The fact that data is available to help anticipate the possible side effects and interactions drugs have with one another is awesome.

There are several drugs that both, prevent and treat osteoporosis. Some medicines slow the rate of bone loss or increase bone thickness. Minute amounts of new bone growth may reduce the danger of breaking bones. It is essential that you take vitamin D and calcium, eat well and exercise when you take osteoporosis prescriptions.

prescription drug